久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

上海非利加實(shí)業(yè)有限公司Logo

熱門詞: 進(jìn)口電動(dòng)溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動(dòng)溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動(dòng)高溫調(diào)節(jié)閥-德國(guó)進(jìn)口電動(dòng)高溫法蘭調(diào)節(jié)閥進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥-德國(guó)進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥

當(dāng)前位置: 首頁(yè) > 所有品牌 > Seattle Genetics
Seattle Genetics
Seattle Genetics Seattle Genetics

美國(guó)Seattle Genetics 
Seattle Genetics公司是美國(guó)的一家專業(yè)研發(fā)治療腫瘤和免疫類疾病的單克隆抗體藥物的生物技術(shù)公司。該公司在抗體偶聯(lián)技術(shù)方面比較有優(yōu)勢(shì),正在研發(fā)多種偶聯(lián)抗癌劑的抗體藥物。

At Seattle Genetics, we are committed to developing innovative antibody-based therapies that improve clinical outcomes for patients with cancer and autoimmune diseases. We are dedicated to addressing unmet medical need, and strive to achieve that goal through an unwavering commitment to excellence in clinical development. Focusing on Clinical Development
Seattle Genetics is a clinical stage biotechnology company advancing a broad product pipeline of antibody-based therapies. Our lead program, brentuximab vedotin (SGN-35), is in a pivotal trial under a Special Protocol Assessment with the FDA for patients with relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is empowered by Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. In addition, we are conducting clinical trials with four other product candidates, lintuzumab (SGN-33), dacetuzumab (SGN-40) and SGN-75, for the treatment of cancer, and SGN-70, for autoimmune diseases. We are also advancing a pipeline of promising preclinical candidates and have robust research and development capabilities that are our engine for innovation and long-term growth.

Our proprietary ADC technology empowers antibodies by stably linking them to cell-killing drug payloads. The drug payload is inactive until released from the antibody inside the targeted cancer cell, thereby sparing normal tissue the toxicity of traditional chemotherapy. In addition to brentuximab vedotin, SGN-75 is an ADC that is in a phase I clinical trial and we are developing several preclinical ADC product candidates, including ASG-5ME, which is advancing towards a planned 2010 clinical trial for solid tumors.

Expanding Our Opportunities Through Collaboration
Collaborating with leading biopharmaceutical companies is a cornerstone of Seattle Genetics' business strategy. Product-focused collaborations, such as our exclusive worldwide collaboration agreement with Genentech (a wholly owned member of the Roche Group) to develop and commercialize dacetuzumab, provide significant near- and mid-term funding while bringing in additional resources and expertise to support, advance and expand promising development programs. Collaboration and license agreements around our proprietary ADC technology also generate cash for the company - more than $75 million to date - while providing further clinical validation of the ADC platform and, in some cases, opening the door to new product development opportunities.
 

關(guān)于我們客戶服務(wù)產(chǎn)品分類法律聲明
主站蜘蛛池模板: 成人精品视频一区二区三区 | www.欧美色图 | 亚洲va国产日韩欧美精品 | 国产在线日韩 | 国产成人不卡亚洲精品91 | 亚洲国产精品一区二区久 | 欧美日韩色图 | 国产欧美日韩精品在钱 | 国产成人综合久久精品下载 | 亚洲视频在线一区 | 亚洲四区| 日韩午夜免费电影 | 国产精品亚洲欧美一级久久精品 | 国产成人+亚洲欧洲 | 亚洲专区欧美专区 | 97久久精品午夜一区二区 | 最近中文字幕电影在线看 | 精品国产一区二区三区久久影院 | 精品国产一区二区三区麻豆小说 | 青青热久久综合网伊人 | 日韩欧美小视频 | 国产第八页 | 国产浴室偷窥在线播放 | 亚洲欧洲第一页 | 国产日韩欧美中文字幕 | 日韩精品欧美亚洲高清有无 | 国产一级特黄a大片99 | 久操久热 | 国产丝袜一区二区三区在线观看 | 欧美日韩a | 极品美女国产精品免费一区 | 亚洲欧美日本在线 | 国内精品久久久久 | 国产激情在线观看 | 91香蕉福利一区二区三区 | 久久91精品国产一区二区 | 亚洲日本一区二区三区高清在线 | 国产码欧美日韩高清综合一区 | 国产又大又粗又猛又爽的视频 | 国内一级片| 欧美激情国产日韩精品一区18 |